由BMI下限和莫迪总理的竞选运动所推动的印度反肥胖市场正在迅速增长,GLP-1型毒品在2026年之前获得牵引力和非专利药物,价格将在2026年之前暴跌。 India's anti-obesity market, fueled by lower BMI thresholds and Prime Minister Modi's campaign, is growing rapidly, with GLP-1 drugs gaining traction and generics set to slash prices by 2026.

到2025年底,印度的抗肥胖市场价值超过1 000千瓦,其46%的CAGR正在激增,其驱动力是修订指导方针,将肥胖性BMI阈值降至25,以及莫迪总理领导的削减食用油消费的全国运动。 India’s anti-obesity market, valued at over ₹1,000 crore by late 2025, is surging with a 46% CAGR, driven by revised guidelines lowering the obesity BMI threshold to 25 and a national campaign led by Prime Minister Modi to cut edible oil consumption. GLP-1类药物,如Mounjaro、Wegovy和Ozempic正在迅速被采用,Mounjaro尽管后来进入,但销售仍领先。 GLP-1 drugs like Mounjaro, Wegovy, and Ozempic are gaining rapid adoption, with Mounjaro leading in sales despite later entry. 随着司美格鲁肽专利于2026年3月到期，包括Cipla、Dr Reddy's和Sun Pharma在内的20多家印度仿制药制造商正准备推出价格低50%至85%的版本，显著提升了可及性。 As the semaglutide patent expires in March 2026, more than 20 Indian generic manufacturers, including Cipla, Dr Reddy’s, and Sun Pharma, are preparing to launch versions priced 50% to 85% lower, significantly improving access. 预计该市场将在两年内超过10亿美元,制药公司将通过数字平台和伙伴关系扩大影响范围。 The market is expected to exceed $1 billion within two years, with pharmaceutical firms expanding reach through digital platforms and partnerships.